Has COVID-19 affected dementia diagnosis rates in England?

Jemma Hazan¹ | Kathy Y. Liu¹ | Jeremy D. Isaacs²,³ | Alistair Burns⁴ | Robert Howard¹

¹Division of Psychiatry, University College London, London, UK
²St George’s University Hospitals NHS Foundation Trust, London, UK
³St George’s, University of London, London, UK
⁴University of Manchester, Manchester, UK

Correspondence
Jemma Hazan, Division of Psychiatry, University College London, Maple House, 149 Tottenham Court Road, London W1T 7BN, UK.
Email: j.hazan@ucl.ac.uk

Funding information
National Institute for Health and Care Research; Medical Research Council, Grant/Award Number: MR/S021418/1

Abstract

Background: The COVID-19 pandemic impacted on the provision of care and routine activity of all National Health Service (NHS) services. While General Practitioner referrals to memory services in England have returned to pre-pandemic levels, the estimated dementia diagnosis rate (DDR) fell by 5.4% between March 2020 and February 2023.

Methods: In this paper we explore whether this reduction is accurate or is an artefact of the way the NHS collects data.

Results: We explore the processes that may have affected national dementia diagnosis rates during and following the COVID-19 pandemic.

Conclusions: We discuss what action could be taken to improve the DDR in the future.

KEYWORDS
assessment, COVID-19, dementia, diagnosis, memory service

Key points

- Despite General Practitioner (GP) referrals to memory services in England returning to levels seen before the pandemic, there was a decline of 5.4% in the estimated dementia diagnosis rate (DDR) from March 2020 to February 2023.
- This paper explores the factors which may have affected the national DDR reduction. These include a backlog in dementia referrals, a reduction in coding of diagnoses, or a decrease in true dementia prevalence secondary to excess COVID-19 deaths which has yet to be reflected in the DDR denominator.
- Further work is suggested to accurately capture dementia prevalence in the United Kingdom (UK). These include an up-to-date multicentre population-based cohort study and adjusting the DDR denominator for factors known to affect dementia susceptibility such as deprivation, rurality, and ethnicity.
INTRODUCTION

The estimated number of people with dementia in the UK is 850,000. Following the 2012 "Prime Minister’s Challenge on dementia," which prioritised increased diagnosis rates, the National Health Service (NHS) Outcomes Framework for 2013/4 established the DDR as a quality indicator. Subsequently, NHS England set a national ambition that two-thirds of all people living with dementia would have a diagnosis; this was translated into a DDR with a numerical value of 66.7%. This was justified by a timely diagnosis of dementia, occurring when the patient and their family are ready to access help, providing an explanation for symptoms and enabling patients and carers to access post-diagnostic support, care planning, and treatment, with consequent improvement in health and care outcomes. The policy has recently been confirmed in the NHS 2023/2024 Operating Guidance.

It should be noted that the economic and societal benefits of dementia diagnosis are largely anecdotal and evidence of reductions in institutionalisation and mortality resulting from receiving a dementia diagnosis is lacking. Nevertheless, the overall benefits of an individual diagnosis, when linked to a meaningful care plan, are overwhelmingly accepted, in line with other areas of clinical practice and are endorsed by the major dementia charities and advocacy organisations. A diagnosis of dementia is associated with advantages in terms of quality of life for both patients and caregivers. In this context, our focus should be directed towards enhancing the overall quality of life.

The COVID-19 pandemic had dramatic consequences for the day-to-day running of all health services, including NHS memory services, and led to a reduction in routine activity. There was a notable decline in referrals and presentations to nearly all mental and physical health services. This decline can be attributed to both reductions in available service provision and a reduction in patient demand. While GP referrals from Primary Care to memory services in England have since returned to pre-pandemic rates, the DDR fell from 67.4% in March 2020 to 62% in February 2023, a reduction of 5.4% shown in Figure 1. It is not clear whether this reduction in the DDR represents a true decrease in diagnostic activity or an artefact of the way that the NHS measures the number of people with dementia in England. We describe potential factors that can impact the national DDR estimates and discuss whether these may have contributed to a lower DDR during the COVID-19 pandemic.

ESTIMATED DEMENTIA DIAGNOSIS RATE (DDR)

The national estimated DDR for England is reported monthly by NHS Digital. The DDR is calculated by dividing the number of people aged over 65 years who have a recorded diagnosis of dementia (from any cause) in each health service region of England, recorded on dementia registers in GP practices in accordance with the Quality and Outcomes Framework guidance (numerator), by the estimated number of people aged over 65 years expected to have dementia in the local population using age- and sex-specific prevalence rates (denominator), multiplied by 100. Since March 2015, 65+ age and sex specific prevalence rates have been taken from the Cognitive Function and Ageing Study. CFAS II, conducted in 2011.

FIGURE 1 Dementia diagnosis rate (DDR) (%) in people over the age of 65 years between February 2019 and February 2023 in England.
investigated the prevalence of dementia in people aged 65 or over, and produced age and sex-specific prevalence rates. The prevalence rates of dementia in CFAS II are lower than those estimated in the previous CFAS I study, conducted in 1993. The calculation underpinning the DDR has always been debated as there are difficulties in estimating the expected number of people with dementia in the population.

There is variability in diagnosis rates between the seven health regions of England and individual GP clusters. Regional variation in national measures occurs across medical and social care. The January 2023 data show a variation in DDR between five regions of England, ranging from 57.3% to 67.2%. For context, in the two years prior, between February 2017 and January 2019, the mean DDR was 67.9 (CI 67.8–68.0). The reported 5.4% point reduction in the national DDR between March 2020 and February 2023 implies that more than 33,000 additional people with dementia are living without a formal diagnosis. There are, however, other potential explanations which we discuss below.

The numerator in the DDR calculation relies on monthly data collected from GP practices in England on the number of registered patients with a recorded dementia diagnosis. This figure can be impacted by several factors.

2.1 | Preferral rates to memory services

An impact of the COVID-19 pandemic was a reduction in GP referral rates. GPs conduct an initial assessment and refer where appropriate to the local memory service for further review. A backlog in referrals might have impacted the DDR.

Although referral rates to memory services dropped sharply in 2020 to only 58% of the number of referrals made in 2019, these have increased again since 2021. At the time of writing, the most recent published data on GP referral rates to memory services in England for September 2022 reveals that the referral rate has returned almost to pre-pandemic levels (Figure 2). If the proportion of patients referred by GPs to memory services who ultimately have dementia is lower for example, due to GPs referring more people with functional cognitive symptoms, “brain fog” caused by long COVID and other non-dementia conditions, this could explain a persistently low DDR despite a recovery in referral rates. However, the proportion of patients referred to memory services receiving a dementia diagnosis was 70% in the 2021 National Audit of Dementia - Memory Services spotlight audit compared to 64% in the 2019 National Memory Service audit, suggesting that the pandemic has not resulted in a rise in non-dementia referrals. Thus, GP referral rates to memory services are unlikely to be a primary explanation for the DDR not yet recovering to pre-pandemic levels, assuming that the backlog of referrals delayed due to the pandemic has been eliminated. However, if this referral backlog has remained, there may be an increased number of people awaiting assessment on memory service waiting lists, leading to delayed dementia diagnoses.

2.2 | Coding of dementia diagnoses

The DDR numerator is reliant on GPs recording the number of people registered with dementia in their care. Dementia diagnoses are recorded by extracting data codes for patients registered with general practices. These codes provide a hierarchical terminology system to encode diagnostic patient information. GPs are required to code the diagnosis whether made in primary care or communicated by secondary or tertiary care. It may be that diminished routine activity during the COVID-19 pandemic resulted in a reduction in the imputation of dementia diagnosis codes by GP practices. This is in the context of increasing primary care clinician shortages which may be impacting coding capabilities. Therefore, even though referral rates were gradually recovering, the coding of dementia diagnoses could have lagged. This could also contribute to the reported drop in the estimated DDR.

Further, the coding system which uses “Read codes” was replaced by Systematized Nomenclature of Medicine Clinical Terms...
“SNOMED CT codes” in the UK in 2020\textsuperscript{23} with the intent of providing improved, consistent and clearer diagnostic coding.\textsuperscript{24} The transition to the new coding system may have reduced the percentage of patients coded with a dementia diagnosis. This transition coincided with the decline in dementia diagnosis rates and may have been a contributing factor. To illustrate this, in 2013 there was a major drive to improve the coding of dementia diagnoses in London general practices which was thought to be contributing to low rates of dementia diagnosis on practice registers. This initiative resulted in an increase in the London DDR, with the proportion of (borough-based) London Clinical Commissioning Groups achieving rates of at least 66.7% increasing from 46% in 2013 to 84% by 2017.\textsuperscript{25}

### 2.3 Mild cognitive impairment diagnoses and the national dementia audits

One potential reason for the drop in DDR during the COVID-19 pandemic could be memory service practitioners diagnosing patients with mild cognitive impairment (MCI) rather than dementia, potentially reflecting more diagnostic uncertainty in the context of patients with mild cognitive impairment (MCI) rather than dementia, pandemic could be memory service practitioners diagnosing patients with mild cognitive impairment (MCI) rather than dementia, poorer quality assessments taking place remotely over the telephone or via video. For example, in 2021, 35% of patients had a virtual appointment.\textsuperscript{26} However, available memory service audit data do not support this concern and available survey data collected from patients after virtual memory service assessments were positive.\textsuperscript{26} Two national memory service audits in the UK were conducted in 2019 and 2021.\textsuperscript{19,27} The 2019 National Memory Service audit was conducted by NHS England and included 85 memory services with data collected on 3978 patients.\textsuperscript{20} The 2021 National Audit of Dementia – Memory Services spotlight audit included 63 memory services with data collected on 5970 patients in England and Wales.\textsuperscript{19} A breakdown of the proportion of diagnoses made in the audit data is provided in Table 1, which shows that the rate of MCI diagnoses has actually decreased between the 2019 and 2021 audits, with a corresponding 6% increase in dementia diagnoses.

### 2.4 Local memory service data

Data were analysed at the local memory service level from South Staffordshire memory service, which is operated by Midlands Partnership NHS Foundation Trust (Figure 3). This provided data about rates of MCI diagnoses which is not collected at national level and is an alternative source to GP registrations. Data are provided by year from April-March. The 2022/23 data are an incomplete dataset, covering April-December. The local trend reveals a reduction in memory clinic referrals, and dementia and MCI diagnoses in 2020/2021. In 2021/2022 the rates of referrals and diagnoses returned to pre-pandemic levels and in fact, exceeded those from 2019/2020. This may support the argument that the lower DDR was in part due to the backlog of cases due to the pandemic. This data, albeit from only one memory service, provides evidence that the number of dementia diagnoses has returned to pre-pandemic levels, contrary to the national data.

### 2.5 Excess dementia deaths due to COVID-19

So far we have considered factors affecting the DDR numerator alone. We must also consider whether an apparent fall in DDR might be an artefactual error due to reduced accuracy of the denominator. The true prevalence of dementia in the population is a function of dementia incidence and mortality rates.\textsuperscript{14} During the COVID-19 pandemic, people with dementia experienced a 25% higher risk of dying during the pandemic period compared to previous years.\textsuperscript{28} Over a quarter (27.5%) of those who died from COVID-19 in England and Wales between March to June 2020 had a diagnosis of dementia, equivalent to 13,840 deaths.\textsuperscript{29} As a result, dementia was the most common pre-existing condition in deaths involving COVID-19 in England and Wales during this period.\textsuperscript{30} The total number of people aged over 65 years on GP dementia registers in England decreased from 437,882 to 415,778 between March 2020 and March 2021,\textsuperscript{11} which closely aligns with the 21,798 reported excess deaths due to COVID-19 in people diagnosed with dementia in England over the same period.\textsuperscript{31} People with a dementia diagnosis also accounted for the largest increase in excess non-COVID-19 related deaths.\textsuperscript{29} Therefore, during lockdown, people with dementia also had a higher risk of death without confirmed COVID-19 which would have impacted on mortality rates in this population further.\textsuperscript{32}

Therefore, it is likely that the COVID-19 pandemic has caused a decline in the prevalence of dementia, such that estimates based on CFAS II are no longer accurate. This would lead to a DDR denominator that is higher than the true prevalence of dementia, which (given the decline in the numerator due to excess mortality) would lead to an apparent reduction of the DDR. In other words, the observed DDR decrease during the pandemic may be driven by a reduction in dementia prevalence due to the disproportionately higher death rate affecting individuals with dementia during the COVID-19 pandemic. This could be elucidated by looking at the stage of dementia of patients on the GP register; deaths from COVID-19 were commoner in people in the later stages of dementia whereas “new” additions tend to be people in the earlier stages.\textsuperscript{33} However, GP dementia registers do not record dementia severity.

### Table 1

<table>
<thead>
<tr>
<th>Audit year</th>
<th>Dementia</th>
<th>Mild cognitive impairment</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>2019</td>
<td>64%</td>
<td>17%</td>
<td>19%</td>
</tr>
<tr>
<td>2021</td>
<td>70%</td>
<td>16%</td>
<td>14%</td>
</tr>
</tbody>
</table>

Note: Data is separate to national data published in NHS Digital and the regional data from South Staffordshire memory service.
The COVID-19 pandemic had a large impact on the activity of primary care and dementia-related secondary care services in England, with an acute reduction in referrals and diagnoses. An increase in cases of undiagnosed dementia may be a byproduct of extended waiting periods for diagnosis, and this would be an important area of further study. At the time of writing, the estimated DDR has not returned to pre-pandemic levels but there are recent signs of a recovery. In this paper we have explored possible reasons for this, including a reduction in diagnostic code imputation or, of concern to those for policymakers, a potential decrease in true dementia prevalence secondary to excess COVID-19 deaths which has yet to be reflected in the DDR denominator. It would also be useful to compare dementia diagnoses rates in England during the COVID-19 pandemic with global data. For example, in Sweden there was a larger decline in dementia diagnoses during 2020 which was not correlated with mortality.

To understand the landscape of dementia diagnoses in England it is imperative that the prevalence rates of dementia are accurately captured. An up-to-date multicentre population-based cohort study is required to understand any changes in the epidemiology of dementia in the wake of the COVID-19 pandemic. This would help to inform policymakers whether further increases in England’s DDR for example, through improved recognition of dementia, access to memory services and investigations, and training of memory service clinicians, is a priority. It is of note that the DDR does not currently inform on the NHS’s performance in diagnosing young-onset dementia, as this population was not included in CFAS II (although the total number of people aged under 65 with dementia is published alongside the DDR). Furthermore, a more granular understanding of dementia prevalence at local level, in which the DDR denominator is adjusted for factors known to affect dementia susceptibility such as deprivation, rurality, and ethnicity will also increase the utility of the DDR as an instrument which guides public policy. Nevertheless, the DDR (perhaps because of its form—a simple percentage rate accessible to all) has maintained the profile of access to diagnosis, an essential element in the dementia pathway.

ACKNOWLEDGMENTS
The authors thank Matthew Evans for providing access to data from The South Staffordshire memory service, Midlands Partnership NHS Foundation Trust. We thank Claire Fry and Mark Thaxter for advice related to the manuscript design. JH is supported by a National Institute for Health Research (NIHR) Academic Clinical Lectureship. KL is funded by the UK Medical Research Council (MR/S021418/1). RH is supported by University College London Hospitals’ NIHR Biomedical Research Centre.

CONFLICT OF INTEREST STATEMENT
AB is the National Clinical Director for Dementia at NHS England (he is a co-author in his academic capacity). JDI is Clinical Director of NHS England (London) dementia clinical network. He has received conference expenses and consultancy fees (paid to his institution) from Roche, a speaker’s fee (paid to his institution) from Biogen and payment (to his institution) from Nestle Health Science for membership of a clinical trial steering committee. The other authors have no conflicts of interest to declare.

DATA AVAILABILITY STATEMENT
Data sharing not applicable to this article as no datasets were generated or analysed during the current study.

REFERENCES


